Drosophila as a model system to study nonautonomous mechanisms affecting tumour growth and cell death by Parvy, Jean-Philippe et al.
Review Article
Drosophila as a Model System to Study Nonautonomous
Mechanisms Affecting Tumour Growth and Cell Death
Jean-Philippe Parvy,1 Joseph A. Hodgson,1 and Julia B. Cordero 1,2
1CRUK Beatson Institute, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road,
Glasgow G61 1BD, UK
2Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate,
Switchback Road, Glasgow G61 1QH, UK
Correspondence should be addressed to Julia B. Cordero; julia.cordero@glasgow.ac.uk
Received 24 November 2017; Accepted 4 February 2018; Published 13 March 2018
Academic Editor: Louise Cheng
Copyright © 2018 Jean-Philippe Parvy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The study of cancer has represented a central focus in medical research for over a century. The great complexity and constant
evolution of the pathology require the use of multiple research model systems and interdisciplinary approaches. This is necessary
in order to achieve a comprehensive understanding into the mechanisms driving disease initiation and progression, to aid the
development of appropriate therapies. In recent decades, the fruit fly Drosophila melanogaster and its associated powerful genetic
tools have become a very attractivemodel system to study tumour-intrinsic andnon-tumour-derived processes thatmediate tumour
development in vivo. In this review, we will summarize recent work on Drosophila as a model system to study cancer biology. We
will focus on the interactions between tumours and their microenvironment, including extrinsic mechanisms affecting tumour
growth and how tumours impact systemic host physiology.
In loving memory of Marcos Vidal, whose work and ideas inspired this review and continue inspiring our work
1. Introduction
Despite being the most studied human disease, cancer
remains a leading cause of mortality worldwide. Nearly 1
in 6 deaths in 2015 was attributable to cancer, according to
the World Health Organization, with an increase of 70% of
new cases projected within the next two decades [1]. The
seemingly restricted success in controlling and reducing the
devastating outcomes of this disease is due, to a great extent,
to the high complexity and variable nature of the pathology.
The current limited understanding of many aspects of cancer
biology is partly imposed by limitations in conventional
animal models of research.
The organismal implications and ultimate outcome of
tumour burden in patients are undoubtedly determined
by a combination of tumour-intrinsic mechanisms and
interactions between tumours and proximal, as well as
distal tissues [2–4]. While cancer research has classically
focused on identifying tumour autonomous processes, there
is a recent growing interest in understanding the nonau-
tonomous mechanisms that control tumour progression [5].
Indeed, pioneering work dating back to the 19th century
established the notion that distant tissues influence tumour
growth and metastasis, when in 1896 Sir Beatson published
a report on the treatment of inoperable cases of breast
carcinomas through ovariectomy [2]. More recently, many
molecular mechanisms have been identified highlighting
the importance of the tumour microenvironment (TME)
in cancer progression [5]. The crosstalk between tumour
cells and their microenvironment often resembles normal
physiological responses: for example, interactions between
cancer cells and the immune system imitate various aspects
of host-pathogen interaction [6]. In such a context, the body
can detect cancer cells and react by mounting an immune
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response, to fight abnormal cell behaviours associated with
the presence of a tumour. However, tumour cells appear
to evolve to turn on new or divert existing physiological
programs in order to evade the action of the immune system
[6, 7].The end result of such a power struggle between cancer
cells and the surrounding tissues will ultimately determine
the outcome of the tumour and its host. Targeting non-
tumoural tissues to counteract cancer growth is becoming
a prime therapeutic strategy, which takes advantage of the
higher genetic stability and lesser susceptibility of normal
cells to escape drug treatments [8]. Hence, the discovery of
novel non-tumour autonomous mechanisms to fight cancer
progression is a promising area of research. However, the
physiological complexity and limitations in the genetic acces-
sibility of mammalian models systems render in vivo studies
of non-tumour autonomous processes difficult to accomplish
in conventional whole animal model systems.
Drosophila melanogaster remains the most powerful
genetic model in research. During the last decades, the devel-
opment of various tumour models, including leukaemia,
neuroblastoma, glioblastoma, colorectal, and ovarian cancer,
has made the fruit fly an attractive in vivo model system to
decipher tumour intrinsic (i.e., tumour cell-autonomous) and
extrinsic (i.e., non-tumour autonomous) molecular mech-
anisms mediating tumour growth and metastasis [9, 10].
Such studies have revealed astonishing conservation in the
processes driving cancer development between flies and
humans [10]. The ability to spatially and temporally regulate
gene expression in tumour-bearing animals, as well as the
low genetic redundancy, is particularly useful for the study
of non-tumour autonomous mechanisms. Major advances
in the understanding of these tumour-extrinsic mechanisms
have been provided through the use of models based on
loss of cell polarity, utilising mutants of the scribble-group of
tumour suppressors genes (scribble: scrib, lethal giant larvae:
lgl, and disc large: dlg), which encode key components of
the basolateral polarity complex [11].These mutations induce
transformation of larval epithelial tissues, called imaginal
discs, into “benign” neoplastic tumours. In this context,
activation of proto-oncogenes, such as Ras or Src, drives
tumour cell proliferation, spreading to distant tissues [12,
13]. During the years following the discovery of scrib-group
genes as tumour suppressors in Drosophila, research has
provided growing evidence that these models are directly
relevant to human conditions. Indeed, scrib and dlg proteins
are known targets of several oncogenic viruses, such as
Human Papillomavirus, the main agent of cervical cancers.
These viruses induce the degradation of the polarity complex
proteins, comprising a key part of the process of malignant
transformation in these conditions [11, 14, 15]. Loss of scrib
has also been shown to work as a tumour suppressor in
human breast, liver, skin, and lung cancers [16–19]. The loss
of the human homolog of the Lgl protein has been involved
in colorectal cancer [20] and hepatocarcinoma [21] and is
associated with an increased risk ofmetastasis in endometrial
cancer [22]. Moreover, similar to its Drosophila homolog,
scrib also cooperates with the Ras oncogene to promote
tumour cell invasion [12, 23].
Here, we discuss recent discoveries in Drosophila that
have shed light into how extrinsic signals influence tumours,
as well as mechanisms that mediate the systemic impact of
tumours in the host. We focus on new findings highlighting
the influence of immunity andmetabolism in cancer progres-
sion and cancer-related disorders.
2. Cellular and Systemic Immunity Influence
Tumour Growth and Cell Death
2.1. e Immune System: A Double-Edged Sword. Work in
mammals has highlighted the immune system as a key
component of the tumour microenvironment (TME), which
plays a critical role in defining tumour outcome. While early
studies on cancer patients support anticancer activity of the
immune system [24], recent research has revealed that immu-
nity can also promote tumour growth and metastasis [25].
However, deciphering the mechanisms of this dual immune
function is a challenging task, mostly due to the complex cel-
lular and molecular composition of the mammalian immune
system [5]. For the past 15 years, the development of cancer
models in Drosophila has allowed the discovery of molecular
mechanisms mediating both pro- and antitumoural immu-
nity. In contrast to mammals, which possess both innate and
adaptive immunity, Drosophila only relies on innate immu-
nity to fight against pathogens and tumours. Additionally,
while mammals have numerous types of white blood cells,
the cellular arm of Drosophila innate immunity includes
only three main cells types—plasmatocytes, lamellocytes,
and crystal cells—commonly called haemocytes. Only plas-
matocytes have been currently reported to be associated
with tumours [26]; however, a possible diversity within the
haemocyte population bound to tumours cannot be excluded.
Even if such macrophage-like cells were unable to infiltrate
tumours as macrophages do, they could still produce a cock-
tail of mammalian-like cytokines leading to inflammation.
While short-term inflammation can be beneficial to protect
the host from challenges, such as those posed by pathogenic
infection, chronic inflammation is associated with tumour
initiation and metastasis in both Drosophila and mammals
[27–29].
Tumour Necrosis Factor alpha (TNF-𝛼) is a major proin-
flammatory cytokine produced within the TME, which was
originally characterised for its ability to induce tumour
death [30]. Consistently, TNF-𝛼’s discovery led to great
expectations for its use as a therapeutic target for cancer.
However, further experiments have revealed a dual role
for TNF-𝛼 as both an anti- and protumour factor [31].
The molecular bases of TNF-𝛼’s antagonistic actions were
poorly understood. However, recent research in Drosophila
has highlighted some key molecular aspects underlying this
dual action of the cytokine. Drosophila possesses a single
TNF-𝛼 homolog called Eiger (Egr) [32, 33], whose role as
an immune proinflammatory cytokine is conserved [34].
The importance of Egr in the TME has been highlighted in
Drosophila tumour models through the use of mutants of
the scrib-group of tumour suppressors genes. Egr expression
is induced in tumours and tumour-associated immune cells
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Figure 1: Immune interactions between larval tumours and their microenvironment (TME). (a) In Drosophila larvae, where tumours are
generated in imaginal discs (tumour in red), the TME consists mostly of immune cells (in green), the fat body (in orange), and the trachea
(in purple). (b) The molecular interactions within the TME are represented in this figure. Positive effects on growth and/or proliferation are
highlighted by lines ending in arrowheads, while lines ending in bars show negative effects, mostly represented by increased cell death. Solid
lines indicate demonstrated interactions and dashed lines potential ones. Both the immune cells and the tumour produce the fly TNFhomolog
Egr. It acts as a double-edge sword depending on the context of the tumour, represented as the Ying-Yang paradigm. Egr is antitumour in
scrib-groupmutant contexts, while being protumour and prometastatic when Rasv12 is present in the scrib-groupmutant genetic background.
The effect of tumour-derived Egr on immune cells is still an open question. Egr is required to activate the Toll pathway in the fat body,
which subsequently promotes tumour cell death in combination with Egr itself, through an unknown signal (questionmark).The interleukin
homolog Upd3 produced by the tumour induces immune cells proliferation, while immune cell-derived Upd3 promotes tumour proliferation
and invasion. While tumour can promote tracheogenesis through incorporation of tumour cells into the tracheal wall (tracheal mimicry),
the effects of trachea on tumour growth and metastasis remain elusive.
[35, 36], much like mammalian TNF-𝛼, which is detected
in tumour cells as well as macrophages and T lymphocytes
[31]. Given the focus of this review, we will only discuss the
extrinsic role of Egr here. However, a tumour-intrinsic role of
the cytokine has also been previously demonstrated [35, 37].
2.2. Cellular Arm of the Immune System and Associated
Cytokines. Experimental evidence showed that immune cell-
derived Egr has antitumoural activity. Patches of scrib, lgl,
or dlg mutant cells generated in imaginal discs, delaminate,
and are mostly removed from the epithelia through cell
competition [12, 37–40]. However, in Egr mutant animals
elimination of polarity deficient clones is abolished, and this
effect can be recapitulated by knocking down Egr specifically
within haemocytes, highlighting a conserved non-tumour
autonomous anticancer function of Egr in Drosophila [35,
36] (Figure 1). Complementarily, loss of the TNF-𝛼 receptor
Grindelwald (Grnd) in scrib mutant cells suppressed their
removal from the epithelia [41]. In those cases, where a
group of mutant cells is generated in a wild-type background,
the elimination of mutant cells through cell competition
relies on Egr-dependent JNK activation, which subsequently
restricts cell proliferation and the survival of mutant cells
[35, 38, 42]. This JNK-dependent toxic effect of TNF-𝛼
is conserved in mammals, as TNF-𝛼 induces cell death
through TNFR1 and subsequent JNK signalling activation
[29]. Recent discoveries of new molecules driving cell com-
petition in Drosophila, including immune response proteins,
may uncover new mechanisms involved in the elimination
of cancer cells from a healthy tissue [43–45]. Egr has also
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been shown to exert antitumoural effects independently of
cell competition. Full mutants animals for scrib-group genes,
where neoplastic tumours develop from the whole imaginal
disc, also show dependency from haemocyte-derived Egr
to trigger JNK activation and tumour cell death [36, 46]
(Figure 1). These studies highlight the importance of the
TME and demonstrate a conserved antitumoural function
of TNF-𝛼-dependent inflammation in Drosophila models of
cancer.
In contrast to the described antitumoural functions,
Drosophila TNF-𝛼 can also exert protumoural effects. Evi-
dence for such a role is provided by studies on tumours
where scrib-complex mutations are associated with a con-
stitutively active form of Ras (Rasv12). Ras is a conserved
proto-oncogene mutated in many cancer types, with a 16%
overall incidence rate in all analysed human tumours [47].
In Drosophila, clones of cells mutated for scrib-complex
proteins and overexpressing Rasv12 fail to be eliminated by
surrounding epithelial cells. Instead, they form neoplastic
tumours that can invade distant tissues [12, 48]. While JNK
is required for cell death in scrib mutant clones, cooperation
with Rasv12 in these clones diverts the function of JNK
pathway activation toward tumour cell proliferation and
invasion [39, 49]. In this context, haemocyte-derived Egr has
also been shown to promote JNK activation, as knockdown
of Egr specifically in immune cells abolished JNK activation
and restricted the ability of scrib, Rasv12 mutant cells to
grow and invade. Strikingly, transplantation of Egr-wild-
type immune cells could rescue the progression of scrib,
Rasv12 tumours, as well as JNK activation, providing the
final demonstration that Drosophila TNF shares protumour
effects with its mammalian counterpart [36] (Figure 1). This
is further supported by observations of high expression levels
of Grnd in scrib, Rasv12 tumours and by data showing that
Grnd knockdown in those tumours also disrupts their growth
and invasive properties [41]. Interestingly, tumours display
increased levels of ROS,which have been reported to promote
haemocyte-dependent Egr secretion and subsequent JNK-
induced proliferation in response to apoptosis, suggesting a
protumoural feedback loopmechanism [50]. Further insights
into the mechanisms mediating this protumorigenic role
of Egr come from a recent demonstration that caspase-
dependent ROS production in cancer cells is required for
the recruitment of macrophages into 𝑠𝑐𝑟𝑖𝑏,Rasv12 tumours
[51]. This work demonstrates that Rasv12-driven tumour pro-
gression requires the activation of Caspases, which function
as tumour promoters. This mechanism is suggested to be
one of the key mediators of the switch of Egr from an
antitumour to a protumour cytokine byRas.Theprotumoural
function of TNF-𝛼 produced by immune cells is highly
reminiscent to the one described in mammalian systems. In
a mouse model of skin carcinogenesis where loss of TNF-𝛼
suppresses tumour formation [52], transplantation of B-cells
from TNF-𝛼 competent mice is sufficient to restore tumour
formation. However, this effect appears to be indirectlymedi-
ated through TNF-𝛼-dependent regulation of T-cell num-
ber [53]. A more direct parallel between TNF-𝛼-dependent
antitumoural responses in flies and humans comes from
work on Kras-dependent intrahepatic cholangiocarcinoma.
In this context, TNF-𝛼 produced by Kuppfer cells (liver-
specific myeloid cells) drives preneoplastic lesions through
JNK signalling pathway activation [54].
The demonstration of antagonistic actions of TNF-𝛼 in
Drosophila and mammalian tumours suggests that the suc-
cessful use of antitumoural immunity as a cancer therapymay
strongly depend on, and must take into consideration, the
genetic composition of the tumour. This is further supported
by data showing that not all neoplastic tumours are sensitive
to Egr. The neoplastic growth induced upon knockdown
of avalanche (avl), a Syntaxin involved in the fusion of
endocytic vesicles to the early endosome, is dependent on
Grnd but escapes the need for Egr [41]. Interestingly, avl
tumours produced high levels of Wingless (Wg) protein,
which is a known target of JNK pathway activation and a
key driver of compensatory proliferation, which is linked to
cancer progression [55, 56]. It is therefore conceivable that the
genetic properties and/or tissue location of a tumour dictate
its sensitivity to different signalling pathways. A recent study
inDrosophila showed thatWg dependent tumours proliferate
independently of the TME and TNF-𝛼/Grnd [57]. Similarly,
tumours bearing combined loss of Rasv12 and hyperactivation
of the nonreceptor tyrosine kinase Src, which also feature
Wg overexpression [58], are largely insensitive to Egr loss
(J.B.C. personal communication). High Wg activity could
therefore be one of the factors rendering tumours insensitive
to TNF-𝛼. The expression of growth factors and activation
of downstream signalling pathways in epithelial tissues in
general and in Drosophila imaginal discs in particular are
usually restricted to certain tissue locations [59, 60]. Recent
work in Drosophila identified the presence of “tumour hot-
spots.” Tumour hot-spots are defined as locations within
tissues where neoplastic mutations are more likely to result
in successful tumoural growths capable of invading normal
tissues and it is a process involving differential activation of
JAK/STAT signalling [61]. It is likely that additional spatially
restricted factors, including gradedmorphogens, such asWg,
Decapentaplegic (Dpp), or Hedgehog (Hh), may influence
“tumour hot-spots” and, therefore, the potential impact of
TNF-𝛼 in this context.
A key phenotypic feature of scrib-group mutants is
the loss of epithelial cell polarity. In tumours lacking lgl,
knockdown of the JNK pathway rescues loss of cell polar-
ity [62]. Loss of cell polarity is required for epithelial-
mesenchymal transition (EMT), which drives tumour pro-
gression, including invasion [63, 64]. Given that Egr is
a major driver of JNK pathway activation, the fly TNF-
𝛼 may be a determinant in the loss of cell polarity in
tissues carrying these neoplastic transformations. Indeed,
Egr regulates asymmetric localisation of determinants of
asymmetric division, Miranda and Prospero, in neuroblasts,
supporting a role for Egr in cell polarity determination [65].
Interestingly, TNF𝛼-dependent loss of cell polarity has been
reported upon induction of chronic inflammation in the
mouse intestine [66]. Likewise, a recent report shows that
TNF𝛼-dependent EMT increases lung cancermetastasis [67].
This possible relationship between TNF-𝛼 and cell polarity
could also be the driving force for TNF-𝛼’s protumour effect
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on Rasv12 expressing cells, as Ras hyperactivation facilitates
the prosurvival function of JNK signalling.
The discovery of other immune-derived cytokines may
have implications on their role in cancer progression through
the TME. Haemocyte-derived Dpp, the fly homolog of
Bone Morphogenetic Protein 2/4 (BMP2/4), a member of
the Transforming Growth Factor beta (TGF-𝛽) signalling
family, can promote intestinal stem cell (ISC) proliferation
in response to infection [68]. A similar effect has been
reported in response to both septic and aseptic injuries
for hemocyte-derived unpaired 2 and 3 (Upd 2/3), the
Drosophila interleukin homologs that function as ligands of
the JAK/STAT pathway [69]. Consistently, in scrib mutant
larvae Upd 3 produced by the tumour induces JAK/STAT
activation in the immune tissues (fat body and haemocytes),
leading to a positive feedback loop that increases Upd 3 levels
in haemocytes, which is required for JAK/STAT-induced pro-
liferation of haemocyte and subsequent tumour suppression
[26] (Figure 1). On the other hand, Upd3 can also impact
JAK/STAT activation within scrib/Rasv12 tumour, where it
cooperates with JNK to promote growth and metastasis [48]
(Figure 1). A protumour effect of JAK/STAT signalling is also
reported in fly leukaemia model, as its activation is sufficient
to drive Drosophila blood cell neoplasia [70].
2.3. e Humoral Immune Response to Tumours. While
the local immune response to tumours is receiving great
interest for the design of new immunotherapies, the role of
systemic immunity in mammals remains elusive. However,
recent advances are highlighting the importance of systemic
immunity to drive successful immunotherapy [71]. Pioneer-
ing work done in Drosophila has demonstrated a role of
systemic or humoral innate immunity in the impairment
of tumourigenesis. The main organ involved in humoral
immunity inDrosophila is the fat body, which processes anal-
ogous functions to the mammalian liver and adipose tissues.
Several conserved immune signalling pathways are activated
in the fat body upon infection, including Toll, immune
deficiency (Imd), and JAK/STAT signalling [72]. Activation
of those pathways leads to the expression of downstream
effectors (antimicrobial peptides, turandots, clotting factors,
serine proteases, TEPs, serpins, and cytokines), which act by
clearing the underlying infection and promoting recovery of
infected tissues [73]. Interestingly, tumour-bearing animals
show activation of the humoral immune response [46].
Unexpectedly, activation of the Toll signalling pathway in
the fat body of tumour-bearing animals could be prevented
by knocking-down the Toll ligand Spaetzle (spz) in haemo-
cytes or by removing Egr from tumours, suggesting that
Egr produced by the tumour promotes Spz production by
haemocytes, which in turn activates the Toll pathway in
the fat body [46]. Toll knockdown in the fat body leads
to increased tumour size and decreased tumour cell death.
Conversely, Toll overexpression is sufficient to induce tumour
cell death and decrease tumour size, a process that requires
haemocyte-derived Egr [46]. All together, evidence shows
that TNF-𝛼-dependent activation of systemic Toll signalling
is an important component of a nonautonomous tumour
suppressor program (Figure 1). The exact mechanisms of
Toll activation, as well as the downstream effector(s) of the
Toll pathway in tumour-bearing animals, remain elusive.
Interestingly, downstream Toll targets expressed following
infection include antimicrobial peptides (AMPs), which have
been reported to exert antitumoural activity in vitro [74].
It is worth mentioning recent technical advances in flies
that have provided new means to study the interactions
between the tumour and the TME or more distant tissues.
Tumour allografts have been a powerful technique to assess
some physiological aspects of tumour growth and metastasis
[57, 75–77], permitting independent genetic manipulation
of tumours and non-tumour host tissues. Furthermore,
it is likely that the use of new genetic tools that allow
manipulation of gene expression independently from the
widely used Gal4 system, such as the LexA/LexAop and
QF/QS/QUAS systems [78, 79], will be extremely useful to
study the influence of distant tissues on tumours. However,
to this end the development of new fly lines is required,
in order to establish these alternative gene-driving systems
for use in large/unbiased screening of processes involved in
tumourigenesis in Drosophila.
2.4. e Tracheal System and Its Role in Tumourigenesis. The
vascular system of vertebrates is known to play a critical
role in the tumour microenvironment, through interaction
with the tumour and the immune system. Indeed, blood
vessels deliver oxygen and nutrients, as well as immune
cells, to all tissues. The fast-growing properties of cancers
lead to the development of some hypoxic areas that are
not vascularised. As a result, angiogenesis is required, in
order to sustain the high demand for oxygen and nutrients
necessary to ensure tumour growth.This therefore constitutes
an attractive target for interfering with tumour development
[80]. In Drosophila, oxygen is provided by the tracheal
system that spreads throughout the animal, thus providing an
analogous system to the vertebrate vasculature.Moreover, the
Drosophila tracheal epithelium is also important in immunity,
as it constitutes a physical barrier to the external milieu
and is able to produce defence proteins [73]. Interestingly,
a recent study showed that tracheogenesis occurs in the
TME of hypoxic tumours in Drosophila. Strikingly, tumour
cells undertake a trachea-specific developmental program
and become incorporated into existing tracheal walls [81]
(Figure 1). This data is reminiscent of the vascular mimicry
process described in several mammalian cancer types, where
tumour cells form functional blood vessel-like structures
that can provide oxygen and nutrients to the tumour [82].
However, while tracheal derived Dpp is shown to influence
ISC proliferation in the fly adult gut [83], the contribution of
tracheogenesis to larval tumour growth and cell death and its
possible contribution to antitumoural immunity remains an
open question.
The studies described above highlight the importance
of cellular and systemic immunity in shaping the tumour
outcome. Critically, they reveal the existence of anti- and
protumour mechanisms mediated by the immune system
that are conserved between flies and humans and also
uncover novel interactions between tumours and the immune
system (Figure 1). However, even in a “simple” model system,
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interactions between tumour and immune cells are extremely
complex. Future work inDrosophilawill help to better under-
stand how the global immune response shapes the TME, and
how tumours are able to influence the antitumoural immune
response via interactions with their microenvironment.
3. Interactions between Host Metabolism
and Tumours
3.1. Tumours Impact SystemicMetabolism. Oneof the striking
effects of tumour burden is the alteration in host metabolism
that occurs as a direct consequence of tumour development.
The origins of the understanding thatmetabolism is altered in
cancer patients can be traced back to the identification of glu-
cose intolerance as the first systemic metabolic abnormality
linked to the presence of a tumour [84].This was followed by
Warburg’s discovery of the abnormal metabolism of glucose
into lactate in tumours, which occurred even in the presence
of oxygen [85]. Later discoveries have revealed a large panel
of metabolic dysfunctions within tumours, which sustain
further growth and proliferation of tumour cells. The high
nutritional demand of tumours can influence nutrient avail-
ability in the TME, as demonstrated by recent work in mouse
models showing that glucose restriction within the TME
inhibits antitumour T-cell function [86, 87]. Furthermore,
the high levels of hormone, peptides, and cytokine secretion
observed during early tumour formation also affectmetabolic
pathways in distant tissues, leading to the hypothesis that
tumours behave as “metabolic dictators” [88]. The biological
complexity and limited genetic tools available in mammalian
models, as well as the lack of physiological relevance of cell
culture models to questions of interorgan communication,
have largely hindered the investigation of altered host and
tumour metabolism. As a model system, Drosophila has
proven very relevant to the investigation of the links between
tumour burden and altered systemic metabolism and the
effects that this can have on both the tumour and host [89]
(Figure 2).
3.2. e Eﬀects of Diet on Tumour Burden. Obesity and type
2 diabetes are common comorbidities in modern society
and are characterised by systemic insulin resistance and
hyperglycaemia. These conditions are associated with an
increased risk of developing cancer and are a risk factor for
cancer mortality [90–94]. Insulin resistance can be modelled
inDrosophila through the use of a high sugar diet, generating
phenotypes that recapitulate the human condition [95].
In this context, small clones of noninvasive tumours cells
transform into highly proliferative, metastatic tumours, due
to the ability of these tumours to evade diet-induced systemic
insulin resistance [58]. Tumours retain sensitivity to insulin
signalling due to the overexpression of insulin receptor, as
a result of elevated expression of Wg. This allows them to
exploit the elevated levels of circulating glucose present in the
context of the high sugar diet and peripheral tissue insulin
resistance (Figure 2). It was later demonstrated [81] that
activation of salt-inducible kinase in tumours from animals
fed a high sugar diet functions to inhibit Hippo signalling,
which facilitates the increase in Wg signalling that mediates
the evasion of insulin resistance by these tumours.However, it
is unclear whether nutrient availability has a universal impact
on tumour growth, or whether any such dependency also
relies on the genetic makeup of the tumour. An additional
example of nutrient dependency can be identified in cells
bearing a loss of function mutation in the tumour suppressor
gene PTEN,which is commonlymutated across a broad range
of cancers [96]. Under normal conditions, PTEN mutant
clones in epithelial wing disc tissue show increased cell size
but do not overgrow or disrupt tissue architecture. However,
upon systemic nutrient restriction PTEN mutant cells dis-
play a proliferative advantage over wild-type cells, which is
dependent on the function of the amino acid transporter
slimfast (slif) [97]. Interestingly, overgrowth of PTENmutant
cells in the context of nutrient restriction was sufficient to
induce systemic nonautonomous effects, decreasing the size
of other tissues in the organism. PTEN mutant cells are
suggested to outcompete distant wild-type cells for access to
nutrients, as genetically driving growth in PTEN-competent
peripheral tissues reduced the overgrowth observed in PTEN
mutant cells [97]. Interestingly, the TOR pathway, a nutrient-
dependent regulator of tissue growth, promotes the activity of
Yki in wing discs [98], which is a known promoter of tumour
growth [99–101]. This may therefore represent a possible
mechanismbywhich increased nutrient availability promotes
tumour growth in these Drosophila models. These findings
demonstrate the drastic effect that the perturbation of host
metabolism by extrinsic factors can have on tumour growth,
how tumours exert systemic effects on distant tissues, and
how the genetic properties of the tumour itself are critical in
mediating this crosstalk.
Parallels can be drawn between the results observed in
these Drosophila models and those found in vertebrates.
Preexisting obesity and diabetes promoted tumour growth in
a rat cancer model [94], while a study of over one million
patients over 26 years identified diabetes as a predictor of
both cancer development and cancer death [102]. Drosophila
cancer models involving diet and obesity are therefore par-
ticularly relevant to the human condition, as the protumour
effects demonstrated in the contexts of these studies appear
to be conserved in higher organisms, and the mediating
factors are environmental influences that are very common
in developed societies. The studies discussed here highlight
new aspects of tumour physiology, suggesting that tumours
are direct competitors to host tissues for nutrients and are
frequently able to outcompete them for access to metabolic
resources through various means (Figure 2). This induces
nonautonomous metabolic effects in host tissues, which are
likely to be beneficial to the tumour.
3.3. Non-Tumour Autonomous Autophagy and Tumour
Growth. Macroautophagy is the process of bulk degradation
of cytoplasmic components, facilitating the removal of
defective organelles and the recycling and remobilising of
cellular resources in times of stress [103]. While intratumour
autophagy has been shown to act as a tumour suppressor,
Rasv12 tumour cells in larval wing discs activate autophagy
nonautonomously in the wild-type cells of the disc,
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Figure 2: Metabolic interactions between tumours and their microenvironment (TME). Interactions between the tumour, the TME, and
other environmental factors are represented in this figure. Solid arrows indicate demonstrated interactions, while dashed lines with question
marks designate putative ones. Nonautonomous metabolic changes in the TME can affect both the TME and the tumour and are generated
through various means. High levels of dietary sugar promote tumour growth and induce systemic insulin resistance in the TME. Tumours
can also perturb TME insulin signalling by the secretion of an insulin-signalling antagonist, ImpL2. Autophagy in the TME promotes tumour
growth through the recycling of amino acids from the TME into the tumour. Expression of the amino acid transporter slif in the tumour is
necessary for this protumour effect. TME autophagy can be triggered by tumour-derived ROS and may also be driven by cytokine signalling
or direct competition with the tumour for nutrients. Both, autophagy and impaired insulin signalling can contribute to tissue wasting and
cancer cachexia. The causes of wasting in the TME and the effects of wasting in these tissues are an increasing research focus. However, the
effects of TME wasting on the tumour remain an open question.
demonstrating the ability of tumours to affect the TME in
this manner [104]. This was further confirmed by another
study reporting systemic non-cell-autonomous autophagy in
animals bearing invasive neoplastic scrib/Rasv12 tumours [77].
Moreover, this study demonstrated that autophagic activity
in tissues both local and distal to the tumour promoted
tumour growth. Inhibition of autophagy in the local TME
is sufficient to significantly inhibit tumour growth and
invasion, an effect that is further enhanced when autophagy
is also blocked in all peripheral tissues. These results directly
demonstrate that non-cell-autonomous autophagy in local
and distant nontumour tissues contributes to tumour growth
and invasion [77]. These data are relevant to vertebrate
models, as autophagy in pancreatic stellate cells has been
demonstrated to promote tumour growth in a pancreatic
cancer cell line implanted into mice [105]. Drosophila
studies have also suggested that microenvironmental
autophagy fuels tumour growth through the mobilisation
of nutrients from these local and peripheral nontumour
tissues (Figure 2). It has been proposed that, in starvation
conditions, autophagy induced by Desat1-dependent Myc
activity may act in a non-cell-autonomous manner to
promote tumour growth [106], while decreased amino acid
transport, by the targeted knockdown of slif in the tumour,
results in a dramatic loss of tumour growth [77]. In human
cell culture models, microenvironmental autophagy has
also been shown to metabolically support human pancreatic
ductal adenocarcinoma in a non-cell-autonomous manner,
through the provision of Alanine as a carbon source [107].
This shows that the data presented in these Drosophila
studies is highly relevant to the vertebrate condition.
The tumour-derived factor(s) that drive the onset of
microenvironmental autophagy are not yet fully defined;
however, ROS signalling is an excellent candidate for further
investigation (see Filomeni et al. [108] for a comprehen-
sive review of ROS and autophagy). Starvation-induced
autophagy is mediated by mitochondrially generated ROS,
via the activation of the TOR pathway [109], while ROS
are elevated in scrib/Rasv12 tumours, and the generation of
mitochondrial ROS is sufficient to induce local autophagy
in wing discs [77]. Manent et al. [104] provide evidence
that ROS derived from tumour cells is sufficient to induce
autophagy nonautonomously in the local microenvironment
and that this also activates protumour JNK signalling in these
cells. Altogether, these studies suggest that tumour-derived
ROS might act as a convergent signal that triggers non-
cell-autonomous microenvironmental autophagy and JNK
signalling in the TME, both of which are protumour events
(Figure 2). There is also some evidence in mouse models to
support the idea that ROSmay play an important role in TME
autophagy. Fibroblasts that suffer oxidative stress induced by
ROS and hypoxia in the TME undergo autophagy, which
acts to degrade mitochondria. This alters the metabolism
of these cells towards aerobic glycolysis, which, combined
with autophagic degradation, is suggested to provide recycled
nutrients from the TME to the tumour to fuel growth [110].
The transfer of energy between tumour and the TME in the
form of metabolites is suggested to maintain the TME in a
protumour setting [88]. Another recent work performed in
cell culture and mouse models suggests that tumour-derived
IL-6 may be a candidate for inducing autophagy in more
tissues distal tissues from the tumour [111]. This work may
represent an interesting novel target for the focus of research
on the effects of peripheral tissue autophagy in Drosophila
cancer models, as the expressions of IL-6-like Upd ligands
are elevated in Drosophila neoplastic tumours [112]. There is
little work exploring the potential interactions between ROS,
autophagy, and Il-6 signalling in the context of the TME, and
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given the studies discussed here, Drosophila may represent a
suitable model for further work into the interactions between
these factors and their combined impact on the tumour
and the TME. The importance of Drosophila studies on
microenvironmental autophagy is reinforced by the apparent
conservation of mechanisms in human patients and other
vertebrate models systems. Further work in Drosophila is
likely to be invaluable in improving our understanding of
howmetabolic changes inTMEmay affect tumours and shape
tumour-host interactions.
3.4. Cancer-Associated Cachexia. One of the best-recognised
outcomes of altered host metabolism in the context of
tumour burden is the condition of cancer cachexia, a para-
neoplastic syndrome that results in the dramatic loss of
muscle and adipose tissue [113]. Cachexia is a highly mul-
tifactorial condition with numerous metabolic aberrations
implicated in the onset of the condition, including perturbed
insulin signalling, systemic hypercatabolism, inflammatory
and immune responses, and deregulation of muscle home-
ostasis [114–117]. Cachexia is a highly deleterious condition,
as it decreases patient tolerance to cancer therapies, negatively
affects quality of life, and increases the risk of mortality,
with up to 30% of cancer patient deaths occurring as a
direct result of cachexia [118, 119]. Importantly, there is no
clear therapeutic gold standard for the treatment of cachectic
patients, in part due to the poorly understood aetiology of the
condition. Cancer cachexia represents an extreme example
of the effect a tumour can have on the host, as the presence
of the tumour generates such a strong alteration of the
host’s metabolic state that it leads to the development of a
novel pathology. There are unanswered questions about the
systemic effects of cachexia beyond the direct effects of the
wasting itself, including whether cachexia has a functional
role that affects the tumour or other tissues.
Two independent models of cancer cachexia have shown
the utility of Drosophila in this field of research [76, 120].
Both reports demonstrated that tumours secrete high levels
of imaginal morphogenesis protein-Late 2 (ImpL2), a secreted
insulin-signalling antagonist that functions by direct binding
toDilp2 [121].These studies also showed that tumour-bearing
flies developed systemic insulin-resistance phenotypes in tis-
sues distal from the tumour.This insulin resistance promoted
tissue wasting, a process that is also likely to occur in human
patients and other animal models [122–126] (Figure 2). RNAi
knockdown of ImpL2 in the tumour was sufficient to reduce
the systemic insulin resistant phenotype and thus partially
rescue the wasting phenotypes observed in peripheral tissues,
without impacting the growth of the tumour [76, 120]. This
work provides an excellent example of the use of Drosophila
cancer models in the field of tumour-microenvironment
interactions. Research into cachexia is an emergent field, and
the identification of a tumour-derived factor that mediates
a systemic effect on host tissue metabolism is an important
example of the ability of Drosophila models to recapitulate
and dissect complex phenotypes. Interestingly, autophagy is
one of the main mechanisms of tissue degradation during
cancer cachexia [111, 127, 128]. There are direct associations
between whether tumours are cachectogenic and their ability
to induce autophagy [111]. Together, these studies raise an
interesting open question as to the functional nature of
cachexia, namely, whether the process is not just deleterious
to the host, but whether it is also beneficial to the tumour,
due to the mobilisation of metabolites from muscle and
adipose tissues. There are also questions as to whether
tumour-inherent properties drive cachexia, and thus whether
genetic factors can be established that mediate cachexia.
Data from human patients suggest this may be the case, as
pancreatic and gastric cancers have a much higher incidence
rate of cachexia when compared to other tumour types
[129, 130]. The Drosophila models discussed here represent a
good opportunity to answer some of these important open
questions.
4. Concluding Remarks
The studies discussed here demonstrate that Drosophila is
a relevant model for studying cancer and its interactions
with the TME, with many parallels to orthologous vertebrate
conditions. Research utilising Drosophila as a model system
has shown that immune and metabolic processes induced in
a nonautonomous manner by the presence of the tumour
are sufficient to feed back to the tumour and alter its
characteristics. This can be shown well in the studies of
microenvironmental autophagy,which is induced in theTME
by the tumour, and serves to support tumour growth and
metastasis [77, 104], and in the dual role of haemocyte-
derived Egr, which can promote or suppress tumour growth
depending on the tumour context [36, 46] (Figures 1 and 2).
Given the effects observed in response to the tumour
there are likely to be interactions between the immune
system and metabolism in this context. Indeed, nutrient
restriction in larvae inhibits TOR signalling in the fat body,
leading to increased levels of circulating Egr. Egr binds
to insulin-producing cells in the brain and suppresses the
production and secretion of progrowth Dilp2 and Dilp5
[131]. As previously discussed, Egr is also a mediator of
tumour-induced immunity with context-dependent pro- or
antitumour function [36, 41, 46].There is therefore the poten-
tial for crosstalk between host tissues with tumour-derived
metabolic derangement and immune pathways inDrosophila.
Work in human cell culture and mouse models has demon-
strated that tumours can alter host immunity via directly
influencing immune cell metabolism. Lactic acid secreted by
the tumour into the TME changes macrophages metabolism,
polarising them towards a tumour-promoting state [132, 133].
These macrophages produce ARG1, a metabolic enzyme that
generates polyamines (metabolites essential for cell division),
which promote tumour growth in this context [134]. Another
example is given by the direct competition for glucose
between tumours and TME T cells, which is also sufficient
to alter T-cell metabolism, suppressing antitumour responses
and highlighting how theWarburg effect is used to escape the
immune system [86, 87].
However, there is a lack of comprehensive understanding
as to how different factors such as diet and metabolism,
immune responses, and tumours interact and cooperate or
synergise when presented together. This is often the case in
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the human condition, for example, in the case of a cancer
patient with diabetes. Drosophila cancer models represent
an excellent basis for the study of the roles these factors
may play, both individually and combined together, and
how nonautonomous signalling inputs might influence both
tumour and host tissue responses. There are likely to be
inevitable questions about the ability of simple Drosophila
tumour models with one or two genetic drivers to fully
recapitulate the complexity of tumour burden in higher ani-
mals, including human patients. However, the simplicity of
thesemodels is likely to prove advantageous when attempting
to dissect the contributing roles of the multiple interacting
factors that comprise tumour-TME interactions.There is also
interesting work on the generation of Drosophila “avatars,”
fly lines that can generate close homologs of tumours from
specific patients, including the numerous genetic aberrations
that drive a particular type of tumour in humans [135].
Such avatars may represent an excellent opportunity to
test principles uncovered in more simple Drosophila cancer
models, in order to investigate whether these discoveries still
hold in a more complex tumour setting, including tumour-
TME responses.
The mechanisms mediating the crosstalk between
tumours and local and distal tissues are still being uncovered.
Improving the understanding of the signalling pathways
that may link together the complex interactions between
host metabolism, immunity, and tumour growth is an
essential aspect towards the unravelling of such crosstalk.
Drosophila models represent an excellent platform for the
continued investigation of these complex interactions,
thanks to the multiple advantages of the model system.
Low genetic redundancy, powerful genetic tools, and the
possibility of tightly controlling not only the genetics of the
tumour but also various aspects of the tumour micro- and
macroenvironment render Drosophila a strong paradigm for
further work into these complex interactions that impact
human health and disease.
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